Lista över produkter

Mycoplasma genitalium (MG)

The hidden STI

 

Mycoplasma genitalium (Mgen) is a complex bacterial infection that is transmitted through direct genital-genital contact. Although often asymptomatic, this sexually transmitted infection (STI) can be responsible for the pain and discomfort associated with cervicitis in women, and causes urethritis in males. The infection is responsible for  approximately:

  • 15 - 20% of nongonococcal urethritis (NGU)1
  • 20 - 25% of nonchlamydial NGU1
  • 30% of persistent or recurrent urethritis1
Uncovering the consequences of Mgen

Though this organism is seemingly in its infancy, research has proven Mgen to be more dangerous than initially realized.


If left untreated, Mycoplasma genitalium can lead to severe health complications for men and women. These include pelvic inflammatory disease (PID), adverse pregnancy outcomes such as preterm delivery and miscarriage, increased risk of HIV acquisition, sexually acquired reactive arthritis, and infertility.3,4

Shining a light on the new
antibiotic resistant STI

 

Antimicrobial resistance threatens the effective prevention and treatment of
bacterial infections, including Mgen. The emergence of antibiotic resistance in Mgen infections has led to a decrease in successful treatment since 20095 and continued empiric use of first-line antibiotics has resulted in the widespread transmission of resistant strains of Mgen.  

Prevalence of Azithromycin Resistance in Mgen around the world6

Resistance-Guided-Therapy-cure-rates-diagram-MG

Informing better treatment pathways

 

Drug regulations and prescription policies play a crucial part in combatting antimicrobial resistance, but clinicians need to embrace new molecular diagnostic methods to detect these challenging strains and any associated antibiotic resistance.


Resistance Guided Therapy for Mgen dramatically improves cure rates4. Utilizing diagnostic tools to identify antimicrobial resistant strains of Mgen enables healthcare practitioners to decide on the most appropriate treatment choice.

References

 

  1. Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines. https://www.cdc.gov/std/tg2015/emerging.htm. Accessed 11 March 2020.
  2. Soni, S. et al., 2019. International Journal of STD and AIDS. 30(10), pp. 938-950.
  3. Ona S, et al. Infect Dis Obstet Gynecol. 2016;2016:4513089.
  4. Denison, HJ., et al. 2016. Clinical Rheumatology. 35(11): 2639–2648
  5. Read TRH, et al. Clinical Infectious Disease 2019;68(4):554–560.
  6. Machalek, DA. et al, 2020. The Lancet Infectious Diseases. 10.1016/S1473-3099(20)30154-7.
  7. Jensen JS. et al., J Eur Acad Dermatol Venereol, 2016;30(10):1650-1656.
  8. Bradshaw CS, et al. PlosOne. 2008;3(11): e3618.
  9. Bissessor M, et al. Clinical Infectious Disease. 2015;60(8):1228-36.
  10. Read TRH, et al. Clinical Infectious Disease. 2016;64(3):250-256.